The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age

Kappelgaard, Anne-Marie; Laursen, Torben

doi:10.1016/j.ghir.2011.09.004

Cited by 32 publications

(31 citation statements)

References 137 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment adherence of rhGH in our study was similar compared to most previous studies concerning rhGH treatment [7,8,11] and other self-administered injectable therapies such as for diabetes mellitus or multiple sclerosis, which is typically about 50-70% [19,21,22,23,24]. Clinical trials also report average adherence rates of only 43-78% [4,5,25].…”

Section: Discussionsupporting

confidence: 85%

Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone

Lass

Reinehr²

2015

Horm Res Paediatr

View full text Add to dashboard Cite

Background: Treatment outcome depends largely on treatment adherence (TA). However, studies analyzing TA in chronic endocrine diseases are scarce and controversial in childhood. Patients and Methods: We studied TA in 103 children treated subcutaneously with growth hormone (GH) and 97 children treated orally with thyroxin. TA was calculated based on the prescription refill rates. The number of GH injections was recorded by an autoinjector device in 23 children treated with GH. Results: The correlation between recorded TA and calculated TA based on prescription refill rates was very good (p < 0.001, r = 0.83). TA was lower (p < 0.01) in pubertal children compared to prepubertal children and in children self-administering their medication compared to those whose drug was administered by their parents, both in GH- and thyroxin-treated children. Overall, 67% of the pubertal children treated with GH and 58% of the pubertal children treated with thyroxin missed at least 1 dose per week. TA was higher (p < 0.001) in children with thyroxin treatment compared to children treated with recombinant human GH (8 vs. 26% missed >3 doses/week). Discussion: Puberty and self-administration of drugs were negative predictors of TA. Therefore, in puberty, prevention and treatment efforts should be undertaken to improve TA, especially when adolescents administer their drugs themselves.

show abstract

Section: Discussionsupporting

confidence: 85%

Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone

Lass

Reinehr²

2015

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Cutfield et al [9] described 66% of all patients as noncompliant (i.e., missing one or more injection per week) over a 4-month study period. In addition, Kappelgaard and Laursen [19] reported in a recent review that up to 50% of children with TS and SGA were noncompliant with GH therapy. Part of the variation in reported compliance rates may be due to the method by which compliance is assessed.…”

Section: Discussionmentioning

confidence: 99%

Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children with Different Growth Disorders

Hartmann¹,

Ittner

Müller-Rossberg

et al. 2013

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: Treatment of children with growth disorders with recombinant human growth hormone is necessary for improved outcomes, including final height. Methods: Adherence data from the Observational Study Saizen®-online, recorded with the easypod™ device collected between October 2009 and May 2011, were analyzed in pediatric patients receiving recombinant human growth hormone treatment for a variety of growth disorders. Results: Data from 75 children (46 boys, 29 girls) with different growth disorders were analyzed over a period of 343 ± 201 (SD) days. Boys and girls showed similar mean ± SD adherence rates of 90.5 ± 3.1% and 92.2 ± 10.7%, respectively. Pubertal children (n = 41) had a significantly lower adherence rate (89.1 ± 13.7%) than prepubertal children (n = 29) (96.5 ± 3.9%; p < 0.005). There were nonsignificant differences in adherence rates according to diagnosis: growth hormone deficiency (n = 48) 91.4 ± 11.0%, small for gestational age (n = 18) 91.1 ± 15.3%, Turner syndrome (n = 6) 86.0 ± 14.5%, and chronic renal failure (n = 3) 99.3 ± 1.0%, although the latter two groups were small. Conclusion: Our data indicate that only a small number of pediatric patients using the easypod device had poor adherence to treatment. Further reliable adherence data are required to identify factors affecting long-term adherence in this population.

show abstract

“…Clinical trials have demonstrated the efficacy and safety of GH treatment . The short‐term safety profile is considered to be good; the incidence of adverse events (AEs) is lower than expected based on patients with natural GH excess (acromegaly) .…”

Section: Introductionmentioning

confidence: 99%

Long‐term safety of growth hormone—A combined registry analysis

Stochholm

Kieß

2017

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age

Cited by 32 publications

References 137 publications

Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone

Low Treatment Adherence in Pubertal Children Treated with Thyroxin or Growth Hormone

Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children with Different Growth Disorders

Long‐term safety of growth hormone—A combined registry analysis

Contact Info

Product

Resources

About